Table 1.
Patient characteristics and conditioning regimen of the study cohort (n = 74) before HSCT and 1-year post HSCT
| Patient characteristic |
Before HSCT |
1-year post HSCT |
P-value | ||
|---|---|---|---|---|---|
| n | % | n | % | ||
| Wt (kg), mean (n = 72) | 34.9 ± 24.6 | 37.7 ± 25.1 | 0.03 | ||
| Wt (z-score), mean (n = 73) | –0.11 ± 1.49 | –0.21 ± 1.20 | 0.31 | ||
| Height (cm), mean (n = 72) | 125.3 ± 35.4 | 128.6 ± 34.8 | 0.008 | ||
| Height (z-score), mean (n = 74) | –0.42 ± 1.16 | –0.77 ± 1.17 | <0.001 | ||
| Hemoglobin (g/dl), mean (n = 71) | 10.4 ± 1.4 | 12.3 ± 1.3 | <0.001 | ||
| Anthracycline exposure | 45 | 60.8 | |||
| Median total lifetime dose (mg/m2) | 150 (120, 195) | ||||
| Min–max total lifetime dose (mg/m2) | 60–375 | ||||
| Conditioning regimen | |||||
| CY | 55 | 74.3 | |||
| Mean dose in pts receiving drug (mg/m2) | 3849 ± 1112 | ||||
| TBI | 39 | 52.7 | |||
| Mean dose in pts receiving therapy (cGy) | 1310 ± 230 | ||||
| Etoposide | 26 | 35.1 | |||
| Mean dose in pts receiving drug (mg/m2) | 1806 ± 790 | ||||
| Carboplatin | 20 | 27.0 | |||
| Mean dose in pts receiving drug (mg/m2) | 1871 ± 329 | ||||
| Anti-thymocyte globulin | 18 | 24.3 | |||
| Mean dose in pts receiving drug (mg/kg) | 77.7 ± 28.7 | ||||
| Melphalan | 18 | 24.3 | |||
| Mean dose in pts receiving drug (mg/m2) | 165 ± 21 | ||||
| BU | 11 | 14.9 | |||
| Mean dose in pts receiving drug (mg/kg) | 17.5 ± 3.9 | ||||
| Thiotepa | 9 | 12.2 | |||
| Mean dose in pts receiving drug (mg/m2) | 4517 ± 4256 | ||||
| Carmustine | 5 | 6.8 | |||
| Mean dose in pts receiving drug (mg/m2) | 300 ± 0 | ||||
| Cytarabine | 5 | 6.8 | |||
| Mean dose in pts receiving drug (mg/m2) | 800 ± 0 | ||||
| Prior mediastinal radiation | 4 | 5.4 | |||
| Inotropic support after HSCT | 5 | 6.8 | |||
| GVHD by 1 year | 13 | 17.6 | |||
Abbreviations: HSCT = hematopoietic stem cell transplant; Max = maximum; Min = minimum; pts = patients.
Mean ± s.d.; interquartile range displayed in brackets [25,75]; comparisons made by the paired Student's t-test.